Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares are trading lower on Thursday as investors digest an update on its European patent fight with Merck, while risk appetite is already soft with the S&P 500 down 0.31% and Healthcare sliding 1.82% (the weakest sector today).
HALO Stock Drops After Merck Keytruda SC Patent Update
Halozyme said a German Higher Regional Court overturned a preliminary injunction that had halted Merck’s Keytruda SC launch in Germany, and the company plans to immediately file an infringement lawsuit in Germany seeking permanent relief.
The company also pointed to an October 2026 Dutch patent court decision that prohibited manufacturing, offering, marketing, using, importing, or holding Keytruda SC stock in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland, and the Netherlands.
“We are disappointed that the Higher Regional Court overturned the preliminary injunction halting the launch of Keytruda SC in Germany. We disagree with the decision and will immediately file an infringement lawsuit against Merck in Germany seeking permanent relief, which is not precluded by today’s decision,” said Mark Snyder, Chief Legal Officer of Halozyme.
Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price forecast of $118.63. Recent analyst moves include:
- Morgan Stanley: Downgraded to Equal-Weight (Raises Price Forecast to $109.00) (Nov. 11)
- Leerink Partners: Downgraded to Market Perform (Raises Price Forecast to $117.00) (Nov. 6)
- Citizens: Market Outperform (Raises Price Forecast to $149.00) (Nov. 6)
How HALO Ranks On Momentum, Quality And Value
Below is the Benzinga Edge scorecard for Halozyme Therapeutics, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Strong (Score: 89.95) — Despite today’s drop, the stock’s broader performance profile still screens as market-leading on momentum factors.
- Quality: Strong (Score: 97.78) — The scorecard is flagging strong underlying business quality versus the broader market.
- Value: Weak (Score: 18.9) — Valuation screens as less compelling, which can make the stock more sensitive when headlines hit.
Top ETFs Holding Halozyme Therapeutics (HALO)
- First Trust NYSE Arca Biotechnology Index Fund (NYSE:FBT): 4.84% Weight
- Invesco S&P MidCap 400 GARP ETF (NYSE:GRPM): 3.22% Weight
- Congress SMid Growth ETF (NYSE:CSMD): 4.29% Weight
HALO Stock Price Activity: Halozyme Therapeutics shares were down 4.19% to $91.79 at the time of publication on Thursday, according to Benzinga Pro data.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.





